Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int

22. REFERENCIAS
1. WHO. Antiretroviral treatment working group treatment white paper. 2010.
2. Siegfried NL, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral
therapy for asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database of
Systematic Reviews 2010. 2010(Issue 2 (In press)).
3. Severe P, Pape J, Fitzgerald D, et al. A randomized clinical trial of early versus standard
antiretroviral therapy for HIV-infected patients with a CD4 cell count of 200-350 cells/mm3
(CIPRATH-001). 49th Interscience Conference on Antimicrobial Agents and Chemotherpy,
San Fransisco, 2009.
4. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al. Major clinical
outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART
at baseline in the SMART study. J Infect Dis 2008;197(8):1133-44.
5. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al. Timing of initiation
of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18
HIV cohort studies. Lancet 2009;373(9672):1352-63.
6. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and
determinants of mortality and morbidity following early antiretroviral therapy initiation in
HIV-infected adults in West Africa. AIDS 2007;21(18):2483-91.
7. Badri M, Bekker LG, Orrell C, Pitt J, Cilliers F, Wood R. Initiating highly active antiretroviral
therapy in sub-Saharan Africa: an assessment of the revised World Health Organization
scaling-up guidelines. AIDS 2004;18(8):1159-68.
8. Wong KH, Chan KC, Cheng KL, Chan WK, Kam KM, Lee SS. Establishing CD4 thresholds
for highly active antiretroviral therapy initiation in a cohort of HIV-infected adult Chinese in
Hong Kong. AIDS Patient Care STDS 2007;21(2):106-15.
9. UNAIDS. Cost estimates: AIDS financing and economics. 2009.
10. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing
with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a
mathematical model. Lancet 2009 Jan 3;373(9657):48-57.
11. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4-guided structured
antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan
ANRS 1269 trial): a randomised trial. Lancet 2006;367(9527):1981-9.
12. Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in
overlapping HIV and TB epidemics. JAMA 2008;300(4):423-30.
13. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV
AIDS 2009;4(4):325-33.
14. Hammer SM, Eron JJ, Jr., Reiss P, Schooley RT, Thompson MA, Walmsley S, et al.
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International
AIDS Society-USA panel. JAMA 2008;300(5):555-70.
131